News headlines about RTI Surgical (NASDAQ:RTIX) have trended somewhat positive on Thursday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RTI Surgical earned a news impact score of 0.02 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.1220857831323 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- RTI Surgical provided eight million biologic implants with zero confirmed incidence of implant-associated infection (dotmed.com)
- Demineralized Allografts Market Analysis and Opportunity Assessment with Emerging Trends, New Growth … (newspharmaceuticals.com)
- Spine Fixation Market Growing Demand, Emerging Trends & Development in depth information by Key Players … (journalhealthcare.com)
- Motion Preservation Devices Market: Comprehensive Growth Analysis by Top Global Leader- Zimmer Biomet Holdings … (businessservices24.com)
- NuVasive, Medtronic, K2M & more: 5 device company notes (beckersspine.com)
Shares of NASDAQ RTIX traded up $0.10 during trading hours on Thursday, reaching $4.80. 75,563 shares of the stock were exchanged, compared to its average volume of 144,838. The firm has a market cap of $277.80, a P/E ratio of 96.00, a price-to-earnings-growth ratio of 2.50 and a beta of 1.57. The company has a current ratio of 3.50, a quick ratio of 1.39 and a debt-to-equity ratio of 0.23. RTI Surgical has a 52 week low of $3.85 and a 52 week high of $6.00.
A number of brokerages have recently weighed in on RTIX. BidaskClub lowered RTI Surgical from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. Craig Hallum upgraded RTI Surgical from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Finally, Zacks Investment Research lowered RTI Surgical from a “hold” rating to a “sell” rating in a research note on Tuesday, March 6th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the stock. RTI Surgical currently has a consensus rating of “Hold”.
WARNING: “RTI Surgical (NASDAQ:RTIX) Receiving Somewhat Positive Media Coverage, Analysis Finds” was reported by BBNS and is the property of of BBNS. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/04/05/rti-surgical-rtix-given-daily-news-impact-rating-of-0-02/2028374.html.
About RTI Surgical
RTI Surgical, Inc, together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.
Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.